drugset / Trial / NCT01610713
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 \[named Sativex® in Canada and also named Sativex® Oromucosal Spray\] for four weeks in an open-label manner.
Timeline
- Start
- 2001-05
- Primary completion
- 2002-07
- Completion
- 2002-07
Publications
- Results Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa.
- Di Marzo V, Centonze D. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes. CNS Neurosci Ther. 2015 Mar;21(3):215-21. doi: 10.1111/cns.12358. Epub 2014 Dec 4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 20 mg | Other |
| Subject | Cannabidiol | Other / unclassified | 25 mg/ml | Other |
| Subject | Cannabidiol | Other / unclassified | 120 mg | Other |
| Subject | delta-9-tetrahydrocannabinol | Other / unclassified | 22 mg | Other |
| Subject | delta-9-tetrahydrocannabinol | Other / unclassified | 27 mg/ml | Other |
| Subject | delta-9-tetrahydrocannabinol | Other / unclassified | 130 mg | Other |